Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy

[1]  M. Preusser.  MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. , 2009, Histology and histopathology.

[2]  J. Menten,et al.  MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. , 2009, European journal of cancer.

[3]  H. Heinzl,et al.  Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker * , 2008, Brain pathology.

[4]  J. Herman,et al.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Shinya Tanaka,et al.  Careful Exclusion of Non-neoplastic Brain Components is Required for an Appropriate Evaluation of O6-methylguanine-DNA Methyltransferase Status in Glioma: Relationship Between Immunohistochemistry and Methylation Analysis , 2008, The American journal of surgical pathology.

[6]  M. Delorenzi,et al.  Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. , 2008, The Journal of molecular diagnostics : JMD.

[7]  A. Iafrate,et al.  "MGMT for pt mgmt": is methylguanine-DNA methyltransferase testing ready for patient management? , 2008, The Journal of molecular diagnostics : JMD.

[8]  A. Brandes,et al.  MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Thomas Hundsberger,et al.  MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome , 2008, International journal of cancer.

[10]  G. Margison,et al.  O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. , 2008, British medical bulletin.

[11]  A. Iafrate,et al.  Molecular Diagnostic Testing in Malignant Gliomas: A Practical Update on Predictive Markers , 2008, Journal of neuropathology and experimental neurology.

[12]  R. Janzer,et al.  Heterogeneity of Human Glioblastoma: Glutathione-S-Transferase and Methylguanine-Methyltransferase , 2008, Cancer investigation.

[13]  I. Whittle,et al.  Randomized Phase III controlled trials of therapy in malignant glioma: where are we after 40 years? , 2008, British journal of neurosurgery.

[14]  B. O'neill,et al.  MGMT Immunohistochemical Expression and Promoter Methylation in Human Glioblastoma , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[15]  Y. Katayama,et al.  Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas. , 2008, International journal of oncology.

[16]  Elizabeth Eisenhauer,et al.  Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. , 2008, The Lancet. Oncology.

[17]  H. Wheeler,et al.  Variation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma , 2008, Journal of Neuro-Oncology.

[18]  A. von Deimling,et al.  Detection of methylation in promoter sequences by melting curve analysis-based semiquantitative real time PCR , 2008, BMC Cancer.

[19]  M. Nagane,et al.  Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. , 2007, Japanese journal of clinical oncology.

[20]  G. Reifenberger,et al.  Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas , 2007, International journal of cancer.

[21]  P. Wesseling,et al.  MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas , 2007, Laboratory Investigation.

[22]  J. Schramm,et al.  Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. , 2007, The Journal of molecular diagnostics : JMD.

[23]  Maria Grazia Bruzzone,et al.  Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival , 2007, Clinical Cancer Research.

[24]  Pierre-Marie Martin,et al.  Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Mikkelsen,et al.  A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue , 2007, Laboratory Investigation.

[26]  K. Hoang-Xuan,et al.  MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities , 2007, Journal of Neuro-Oncology.

[27]  R. McLendon,et al.  Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma , 2006, Molecular Cancer Therapeutics.

[28]  S. Rogers,et al.  Promoter methylation of P16, RARβ, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing , 2006, British Journal of Cancer.

[29]  P. Loehrer.  Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma , 2006 .

[30]  I. Ferrer,et al.  Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas , 2005, Clinical Cancer Research.

[31]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[32]  Luca Regli,et al.  Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.

[33]  Carol Walker,et al.  Characterisation of molecular alterations in microdissected archival gliomas , 2001, Acta Neuropathologica.

[34]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[35]  R. McLendon,et al.  DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.